Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial

Diffuse large B-cell lymphoma (DLBCL), with high coexpression of BCL2 and MYC proteins (DE lymphoma), is considered an adverse prognostic indicator associated mostly with non-germinal center B-cell–like (non-GCB) DLBCL. BCL2/MYC overexpression is associated with B-cell receptor (BCR) pathway activat...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Peter W. M., Balasubramanian, Sriram, Hodkinson, Brendan, Shreeve, S. Martin, Sun, Steven, Srinivasan, Srimathi, Steele, Andrew J., Vermeulen, Jessica, Sehn, Laurie H., Wilson, Wyndham H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188634/
https://www.ncbi.nlm.nih.gov/pubmed/36696540
http://dx.doi.org/10.1182/bloodadvances.2022009389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188634/
https://www.ncbi.nlm.nih.gov/pubmed/36696540
http://dx.doi.org/10.1182/bloodadvances.2022009389

Ejemplares similares